度普利尤单抗治疗患者发生的脂溢性皮炎和脂溢性银屑病：两例病例报告。
Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports.
作者信息
Al-Janabi Ali, Marsland Alexander M
机构信息
The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre Salford UK.
Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Salford UK.
出版信息
Clin Case Rep. 2020 May 9;8(8):1458-1460. doi: 10.1002/ccr3.2871. eCollection 2020 Aug.
Abstract
Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.
摘要
度普利尤单抗引起的皮肤不良事件可能多种多样；这就需要进行广泛的鉴别诊断，以识别看似矛盾的反应。在不停用度普利尤单抗的情况下，有可能同时治疗不良事件。
相似文献
1
Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports.度普利尤单抗治疗患者发生的脂溢性皮炎和脂溢性银屑病：两例病例报告。
Clin Case Rep. 2020 May 9;8(8):1458-1460. doi: 10.1002/ccr3.2871. eCollection 2020 Aug.
2
Facial and neck erythema associated with dupilumab treatment: A systematic review.与度普利尤单抗治疗相关的面部和颈部红斑：系统评价。
J Am Acad Dermatol. 2021 May;84(5):1339-1347. doi: 10.1016/j.jaad.2021.01.012. Epub 2021 Jan 8.
3
IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.IL-4/13 阻断剂与超过 37000 例度普利尤单抗报告中的睡眠相关药物不良反应：来自世界卫生组织个体病例安全报告药物警戒数据库（VigiBase™）的大数据和机器学习分析。
Eur Rev Med Pharmacol Sci. 2022 Jun;26(11):4074-4081. doi: 10.26355/eurrev_202206_28977.
4
Case report: Dupilumab leads to an increased chance of head and neck infection in atopic dermatitis patients.病例报告：度普利尤单抗会增加特应性皮炎患者头颈部感染的几率。
Front Med (Lausanne). 2023 Mar 8;10:1027589. doi: 10.3389/fmed.2023.1027589. eCollection 2023.
5
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.特应性皮炎患者度普利尤单抗相关眼表疾病的管理。
Swiss Med Wkly. 2021 Aug 20;151:w30020. doi: 10.4414/SMW.2021.w30020.
6
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
7
Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.特应性皮炎成年患者中与度普利尤单抗相关的皮肤不良事件：一项回顾性研究。
J Dermatol. 2023 Jul;50(7):880-887. doi: 10.1111/1346-8138.16764. Epub 2023 Mar 13.
8
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.特应性皮炎中对度普利尤单抗反应不足及不良反应的管理。
J Am Acad Dermatol. 2022 Mar;86(3):628-636. doi: 10.1016/j.jaad.2021.06.017. Epub 2021 Jun 11.
9
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.治疗过敏疾病时的度普利尤单抗相关不良事件。
Clin Rev Allergy Immunol. 2022 Jun;62(3):519-533. doi: 10.1007/s12016-022-08934-0. Epub 2022 Mar 11.
10
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
引用本文的文献
1
Mapping the psoriasis research landscape: A comprehensive bibliometric analysis from 2012-2023.绘制银屑病研究图谱：2012-2023 年的全面文献计量分析。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241290341. doi: 10.1177/03946320241290341.
2
More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis.更多的酵母，更多的问题？：重新评估马拉色菌在脂溢性皮炎中的作用。
Arch Dermatol Res. 2024 Mar 12;316(4):100. doi: 10.1007/s00403-024-02830-7.
3
"De Novo" Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature.度普利尤单抗诱发的“新发”银屑病及银屑病复发：三例新病例并文献复习
J Clin Med. 2023 Sep 29;12(19):6291. doi: 10.3390/jcm12196291.
4
Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.度普利尤单抗相关银屑病和银屑病样表现：范围综述。
Dermatology. 2023;239(4):646-657. doi: 10.1159/000530608. Epub 2023 Apr 26.
5
Upadacitinib-induced paradoxical face and scalp dermatitis: A case report of a novel sequela.乌帕替尼诱发的矛盾性面部和头皮皮炎：一例新型后遗症的病例报告
SAGE Open Med Case Rep. 2023 Apr 14;11:2050313X231164271. doi: 10.1177/2050313X231164271. eCollection 2023.
6
Risks and safety of biologics: A practical guide for allergists.生物制剂的风险与安全性：过敏症专科医生实用指南。
World Allergy Organ J. 2023 Jan 16;16(1):100737. doi: 10.1016/j.waojou.2022.100737. eCollection 2023 Jan.
7
Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients.度普利尤单抗治疗后特应性皮炎患者出现的肢端红斑：3例病例报告
Asia Pac Allergy. 2022 Jan 10;12(1):e1. doi: 10.5415/apallergy.2022.12.e1. eCollection 2022 Jan.
本文引用的文献
1
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.接受度匹鲁单抗治疗的特应性皮炎患者出现反常性头颈部红斑的临床和组织病理学特征：病例系列研究。
Br J Dermatol. 2020 Oct;183(4):745-749. doi: 10.1111/bjd.18730. Epub 2019 Dec 22.
2
Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.度普利尤单抗治疗成人特应性皮炎期间银屑病样皮疹的发生：病例系列
Dermatol Ther. 2019 Nov;32(6):e13142. doi: 10.1111/dth.13142. Epub 2019 Nov 21.
3
Rosacea associated with dupilumab therapy.与度普利尤单抗治疗相关的酒渣鼻。
J Dermatolog Treat. 2021 Feb;32(1):114-116. doi: 10.1080/09546634.2019.1624683. Epub 2019 Jun 9.
4
Assessment of the Development of New Regional Dermatoses in Patients Treated for Atopic Dermatitis With Dupilumab.评估度普利尤单抗治疗特应性皮炎患者中新出现的区域性皮肤病。
JAMA Dermatol. 2019 Jul 1;155(7):850-852. doi: 10.1001/jamadermatol.2019.0109.
5
Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.度普利尤单抗治疗患者中炎症性关节炎和附着点炎的发生：病例系列
Br J Dermatol. 2019 Nov;181(5):1068-1070. doi: 10.1111/bjd.18031. Epub 2019 Jul 18.
6
Psoriasis induced by dupilumab therapy.度普利尤单抗治疗引起的银屑病。
Clin Exp Dermatol. 2019 Apr;44(3):e49-e50. doi: 10.1111/ced.13901. Epub 2019 Jan 17.
7
Erythrodermic presentation of psoriasis in a patient treated with dupilumab.接受度普利尤单抗治疗的患者出现红皮病型银屑病。
JAAD Case Rep. 2018 Aug 15;4(7):708-710. doi: 10.1016/j.jdcr.2018.05.014. eCollection 2018 Aug.
8
Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases.两例血清免疫球蛋白 E 水平升高的银屑病患者使用乌司奴单抗后特应性皮炎症状加重。
J Dermatol. 2018 Jun;45(6):732-734. doi: 10.1111/1346-8138.14295. Epub 2018 Mar 22.
9
Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.成人中重度特应性皮炎患者使用度普利尤单抗的不良反应：一项荟萃分析。
Int Immunopharmacol. 2018 Jan;54:303-310. doi: 10.1016/j.intimp.2017.11.031. Epub 2017 Nov 25.
10
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.两项度普利尤单抗治疗特应性皮炎的 3 期临床试验。
N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
Zotero 插件